Live updates: White House prepares for Trump-Putin meeting in Alaska tomorrow
Date: 10 min ago
Title: Putin: US making "energetic and sincere efforts" to end war in Ukraine
Content:
During a meeting with top Russian officials ahead of tomorrow's summit in Alaska with US President Donald Trump, Russian President Vladimir Putin said the United States is taking action to stop the war in Ukraine.
Before he travels to Alaska, Putin chaired a meeting that included members of the negotiating team that will join him at the summit, including Foreign Minister Sergey Lavrov, to brief them on 'how the negotiation process on the Ukrainian crisis is going.'
'The current American administration … is making, in my opinion, quite energetic and sincere efforts to stop the hostilities, stop the crisis and reach agreements that are of interest to all parties involved in this conflict,' Putin said.
Putin also said that peace will be strengthened between Russia and the US — as well as the wider world — if the two countries reach agreements in the field of strategic offensive arms control.
Update:
Date: 10 min ago
Title: US and Russia teams will discuss Ukraine war and economic cooperation in Alaska summit, Kremlin says
Content:
A senior aide to Vladimir Putin has shared details of the plans for the Russian leader's meeting with President Donald Trump in Alaska tomorrow, saying the delegations would discuss the war in Ukraine and potential economic cooperation.
Yury Ushakov, Putin's foreign policy aide, told reporters that the summit will be held at the Joint Base Elmendorf-Richardson military site in Anchorage, Alaska, at 11.30 a.m. local time (3:30 p.m. ET) on Friday.
The presidents will first have a one-on-one conversation, with the help of interpreters, before continuing talks over a business lunch, according to Ushakov. He said the length of the talks 'will depend on the presidents.'
Both the Russian and US delegations will be comprised of five members, with further groups of experts nearby, he said.
Ushakov said the teams are expected to focus on the settlement of the war in Ukraine, as well as prospects of cooperation between Russia and the US in trade and economic issues.
'Following the talks, Vladimir Putin and Donald Trump will hold a joint press conference, in which they will sum up the results of the negotiations,' Ushakov said.
The Russian delegation: As well as Ushakov, Russia's team comprises Foreign Minister Sergey Lavrov, Defense Minister Andrey Belousov, Finance Minister Anton Siluanov and Kirill Dmitriev, a senior negotiator and head of Russia's sovereign wealth fund.
The aide also noted that the talks will be held near the burial site of Soviet pilots in Alaska.
For subscribers: Read chief global affairs correspondent Matthew Chance's analysis of what Putin really wants from Trump.
Update:
Date: 10 min ago
Title: Analysis: Trump has set deadlines for peace in Ukraine with zero results
Content:
President Donald Trump says Russia will face 'consequences' if Russian President Vladimir Putin does not agree to stop the war in Ukraine during the leaders' meeting in Alaska tomorrow.
CNN's Kate Bolduan shows how Trump has made similar remarks in the past without producing any results.
President Donald Trump says Russia will face "consequences" if Russian President Vladimir Putin does not agree to stop the war in Ukraine. CNN's Kate Bolduan shows how Trump has made similar remarks in the past without producing any results
You can also watch the video here on YouTube.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
I'm a Real Estate Agent: It's Getting Harder To Sell Your Home in These 10 Cities
Sellers have held the upper hand in the U.S. housing market for so long that buyers might wonder when the dynamic will finally change in their favor. In fact, that might already be happening. The housing market has become more 'buyer-friendly' amid a rise in inventory in many parts of the country, according to a new report from That doesn't mean it's a buyer's market now — at least not yet. High mortgage rates are a headwind for buyers, and list prices remain historically expensive. Meanwhile, some markets continue to see stiff competition, which means available homes tend to go quickly. Be Aware: Learn More: A Clever Real Estate study of 2024 housing data found that nationwide, the median days on market for listed homes was 40 days. But that figure was much higher in some states — including Hawaii (80 days), Montana (78), Louisiana (69), South Carolina (68) and South Dakota (65). At the city level, some once-hot housing markets have started to cool considerably, causing sellers to slash prices to find enough buyers. GOBankingRates spoke with real estate experts about the current state of the housing market and which cities are seeing challenges when it comes to selling homes. Housing Trends Experts Are Seeing Ken Corsini, co-founder of Red Barn Homebuyers in Georgia, said he's seeing homes 'linger much longer' in Florida cities like Miami, Orlando, Jacksonville and West Palm Beach, as well as in Houston, Nashville, Austin (Texas) and Tucson (Arizona). 'These markets are cooling off fast because sellers are clinging to yesterday's prices, but buyers have the upper hand thanks to high rates and growing inventory,' Corsini told GOBankingRates. 'In places like Miami, sellers are even pulling their listings instead of negotiating, which shows how out of sync expectations have become.' This dynamic has spread to smaller towns as well, according to Matt Taschner, CEO of Sota Home Buyers, a Minnesota-based real estate buyer. 'Two markets that are really showing slow selling at the moment and where listed homes are staying on the market longer than they were a year or two ago are Naples, Florida, and Longview, Texas,' Taschner told GOBankingRates. 'The median number of days that homes are sitting on the market in both is well above the national average… All in all, there is greater buyer reluctance and price resistance, even in areas that were previously red hot.' Here's a look at 10 cities where it's getting harder to sell a home. The figures are from Zillow as of Aug. 7, 2025. Austin, Texas Typical home values: $523,769 1-year value change: -6.5% Houston, Texas Typical home values: $269,422 1-year value change: -2.8% Consider This: Jacksonville, Florida Typical home values: $290,108 1-year value change: -3.8% Longview, Texas Typical home values: $232,498 1-year value change: +2.1% Miami, Florida Typical home values: $588,264 1-year value change: -0.7% Naples, Florida Typical home values: $564,809 1-year value change: -7.0% Nashville, Tennessee Typical home values: $445,803 1-year value change: -0.9% Orlando, Florida Typical home values: $381,502 1-year value change: -2.9% Tucson, Arizona Typical home values: $331,789 1-year value change: -2.3% West Palm Beach, Florida Typical home values: $397,047 1-year value change: -4.0% More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 Mark Cuban Tells Americans To Stock Up on Consumables as Trump's Tariffs Hit -- Here's What To Buy How Much Money Is Needed To Be Considered Middle Class in Your State? This article originally appeared on I'm a Real Estate Agent: It's Getting Harder To Sell Your Home in These 10 Cities
Yahoo
17 minutes ago
- Yahoo
Here's How Much You'll Pay in Mortgage Interest in These 15 Cities — Is Buying a Home Still Worth It?
House hunters in the United States continue to face the double whammy of near-record home prices and high mortgage rates. In some cases, the mortgage interest alone might be enough to dissuade people from buying a home. Try This: For You: Nationally, the average rate for a 30-year fixed-rate mortgage is 6.74%, according to the latest data from Freddie Mac. That hasn't changed much over the past year but it remains well above the sub-3% rates seen earlier in the decade. Meanwhile, the Federal Reserve reports that homes in the U.S. sold for a median price of $410,800 during the 2025 second quarter — down from a record of $442,600 in late 2022 but still much higher than the historical average. GOBankingRates reveal how much mortgage interest you'll pay in 15 cities — and whether buying a home in these popular spots are still worth it. Ballooning Interest Payments The combination of pricey housing and high mortgage rates means some homeowners will spend a lot more in mortgage interest than most Americans pay for a single home. A recent study from JW Surety Bonds found that homeowners in major U.S. cities will spend an average of nearly $490,000 on interest over the lifetime of a 30-year loan. That number was based on a mortgage interest rate of 6.89%. Check Out: For its study, JW Surety Bonds collected data from Freddie Mac and Zillow and analyzed historical mortgage interest rates and median home values across the top 50 most populous U.S. cities. Researchers also surveyed 970 U.S. adults to get their pulse on the current housing market. Nearly one-quarter (23%) or potential first-time homebuyers said the most they would be willing to pay in lifetime interest is $200,000 to $300,000. That's not only much less than what the average buyer would pay under current conditions — it doesn't even come close to what homeowners in some cities face. These Cities Have the Highest and Lowest Interest Payments Homeowners in the priciest U.S. cities can expect to pay more than $1 million over the course of a 30-year mortgage loan at current rates. Here's how much you'll pay in mortgage interest in the 10 most expensive cities for average home prices: San Jose, California: $1,665,279 San Francisco, California: $1,424,814 San Diego, California: $1,124,184 Los Angeles, California: $1,070,928 Seattle, Washington: $972,213 Long Beach, California: $935,920 New York, New York: $841,886 Boston, Massachusetts: $831,328 Washington, DC: $663,344 Miami, Florida: $646,056 Here are the five cities with the cheapest home prices and lowest interest payments: Detroit, Michigan: $83,959 Memphis, Tennessee: $160,339 Baltimore, Maryland: $204,197 Oklahoma City, Oklahoma: $220,772 Milwaukee, Wisconsin: $228,521 Is Buying a Home Worth It? Whether you should buy a home right now mainly depends on your financial situation. If you're financially comfortable, with little debt and enough saved up for a large down payment, there's no reason you shouldn't go ahead and buy a home even with mortgage rates at their highest point in decades. On the other hand, Ramsey Solutions recommends holding off on a new home if any of the following apply to you: You have a lot of current debt that needs to be paid down. You don't have a full emergency fund that can cover at least three to six months of typical expenses. You haven't saved enough for a down payment that can cover at least 5% to 10% of the home price for first-time buyers, or 20% of the home price for most others. You can't afford the house payment based on your current income and budget. More From GOBankingRates 5 Old Navy Items Retirees Need To Buy Ahead of Fall The New Retirement Problem Boomers Are Facing This article originally appeared on Here's How Much You'll Pay in Mortgage Interest in These 15 Cities — Is Buying a Home Still Worth It? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
U.S. mRNA Therapeutics CDMO Market to Hit Valuation of US$ 6.27 Billion by 2033
Shifting from its pandemic response origins, the market is diversifying into new vaccines and oncology. Asset-light biotechs fuel this growth, making specialized CDMOs essential partners for advancing next-generation mRNA therapies into the clinic and beyond. Chicago, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The US mRNA therapeutics CDMO market was valued at US$ 1.78 billion in 2024 and is expected to reach US$ 6.27 billion by 2033, growing at a CAGR of 15.01% during the forecast period 2025–2033. The outlook for the US mRNA therapeutics CDMO market is exceptionally bright, anchored by a vast clinical pipeline poised for commercialization. As of early 2024, an incredible 1,503 mRNA programs were in development, creating a deep reservoir of future manufacturing demand. This is exemplified by Moderna, which entered 2024 with 45 programs, including nine in late-stage development. The transition from R&D to market is accelerating, with Moderna anticipating up to three potential product approvals in 2025 alone. Looking further, the company is targeting the delivery of up to 10 product approvals by 2027, creating a clear, multi-year roadmap for sustained CDMO engagement from clinical scale-up to commercial supply. Download Sample Pages: This promising pipeline is backed by extraordinary financial commitments and strategic infrastructure expansion. In 2024, Lonza acquired a major U.S. biologics site for $1.2 billion and plans to invest another $560 million in upgrades. Venture capital is also pouring in, with Strand Therapeutics raising $153 million in August 2025 and Centivax securing $45 million in July 2025. Government confidence remains high, highlighted by BARDA's $590 million award to Moderna in January 2025 for influenza preparedness. This massive influx of capital ensures that the manufacturing capacity and technological capabilities will be in place to meet the escalating demands of this innovative therapeutic frontier. Key Findings US mRNA Therapeutics CDMO Market Market Forecast (2033) US$ 6.27 billion CAGR 15.01% Top Drivers Sustained government funding for pandemic preparedness and biodefense initiatives. Rapid clinical development timelines attracting investment for diverse therapeutic areas. Expansion of mRNA applications into oncology and rare diseases. Top Trends Integration of AI for optimizing mRNA sequence and LNP design. Development of next-generation delivery systems beyond traditional lipid nanoparticles. A shift toward personalized mRNA cancer vaccines and therapeutics. Top Challenges Securing the supply chain for critical raw materials (plasmids, enzymes). Navigating evolving and complex regulatory pathways for novel therapeutics. Managing the high cost of goods for personalized therapies. An Expanding Clinical Pipeline Fuels Intense Manufacturing and Development Demand The depth and breadth of the clinical pipeline serve as the primary engine for the US mRNA therapeutics CDMO market. As of early 2024, an impressive 1,503 mRNA programs were listed on a testament to the technology's burgeoning potential. Industry leader Moderna entered 2024 with 45 therapeutic and vaccine programs in its pipeline, nine of which are in late-stage development. This activity is not confined to established players; in February 2024, ReCode Therapeutics initiated a Phase 1 clinical study for its mRNA therapeutic candidate, RCT2100, by dosing its first volunteer. The focus on oncology is particularly intense. In May 2025, Moderna initiated a Phase 1 trial for its novel pan-tumor antigen therapy, mRNA-4106. Furthermore, its partnership with Merck is advancing a Phase 3 trial for the individualized neoantigen therapy (INT), mRNA-4157, for high-risk melanoma, with a second Phase 3 trial enrolling patients for non-small cell lung cancer. Beyond cancer, Moderna also announced positive Phase III efficacy results for its seasonal flu vaccine (mRNA-1010) in June 2024, while at least three therapies using novel RNA editing technology entered clinical trials in 2024. Strategic Regulatory Actions and Government Funding Shape Market Contours Federal oversight and funding are pivotal forces sculpting the competitive landscape and demand cycles of the US mRNA therapeutics CDMO market. On August 22, 2024, the U.S. FDA took decisive action by approving the updated 2024–2025 formula of Moderna's Spikevax and Pfizer-BioNTech's Comirnaty. Concurrently, Emergency Use Authorizations (EUAs) were granted for both vaccines for younger age groups. This followed FDA guidance from June 2024 advising manufacturers to target a monovalent JN.1-lineage, which was later updated to the KP.2 strain. Government funding continues to be a powerful catalyst. In March 2025, Arcturus Therapeutics secured a BARDA contract valued at up to $63 million for a bird flu vaccine trial. Similarly, the U.S. government awarded Moderna $590 million in January 2025 to accelerate its mRNA-based H5N1 vaccine development, building on a previous $176 million award in 2024. Tiba Biotech also received $749,999 from BARDA in July 2024 for an influenza treatment. However, in a significant policy shift, the Department of Health and Human Services cancelled nearly $500 million in contracts for 22 different mRNA projects in August 2025, highlighting the dynamic nature of government priorities. Fueling Innovation Through Strategic Corporate and Venture Capital Investments The immense promise of mRNA technology is attracting substantial financial backing, which directly fuels R&D and manufacturing activities within the US mRNA therapeutics CDMO market. This influx of capital is enabling emerging biotechs to advance their novel platforms and pipelines. In a significant vote of confidence, Strand Therapeutics, a developer of programmable mRNA therapeutics, raised an impressive $153 million in a Series B financing round in August 2025. This recent funding builds upon the $97 million the company had previously raised to support its research efforts. The investment momentum is also visible in specialized niches, with Centivax, a Silicon Valley startup developing a universal flu mRNA vaccine, securing a $45 million Series A round in July 2025. Furthermore, major pharmaceutical collaborations provide crucial non-dilutive funding and validation; Merck underscored its commitment to the space by paying Moderna an option exercise fee of $250 million back in October 2022 to jointly develop personalized mRNA cancer vaccines. Performance Metrics of Key Players Shaping the Competitive Landscape The financial performance and strategic planning of market leaders in the US mRNA therapeutics CDMO market offer a clear quantitative measure of the industry's health and future CDMO demand. Moderna reported substantial product sales of approximately $6.7 billion for the full year 2023. The company initially forecasted sales of around $4 billion for 2024, which was later revised in January 2025 to a range of $3.0 to $3.1 billion. Of these 2024 sales, a significant $1.7 billion were generated within the United States. Looking ahead, Moderna anticipates having an ending cash balance of approximately $6.0 billion in 2025 and is implementing cost-saving measures, including an additional $500 million in savings planned for 2026. Its cash operating costs were already reduced by over 25 percent in 2024 compared to 2023, with a goal to reduce 2025 cash costs by a further $1 billion. Meanwhile, competitor Pfizer posted strong sales of $5.35 billion for its mRNA vaccine, Comirnaty, in 2024, reinforcing the continued commercial relevance of established mRNA products. Fortifying the Foundational Supply Chain for Advanced mRNA Manufacturing A resilient and technologically advanced supply chain for critical raw materials is the bedrock of the entire US mRNA therapeutics CDMO market. Recognizing this, key suppliers are making substantial investments to boost capacity and innovation. In December 2024, Aldevron, a Danaher subsidiary, began operations at its new GMP plasmid DNA facility in Fargo, North Dakota, specifically to supply mRNA vaccine developers. In a similar move, Cytiva, also part of Danaher, completed an expansion of its Marlborough, MA site in February 2025, adding crucial new capacity for high-purity enzymes and nucleotides. Innovation is also accelerating, with TriLink BioTechnologies introducing a new class of modified nucleotides in February 2025 optimized for the long-read mRNA sequences used in oncology. TriLink also partnered with Johns Hopkins University in May 2024 to accelerate RNA discovery research. Therapeutic developers are also securing their supply lines, as seen in Moderna's December 2024 acquisition of a U.S.-based enzyme supplier and its November 2024 strategic agreement with Thermo Fisher Scientific for custom raw materials. CDMO Capacity Expansion Meeting Surging Next-Generation Therapeutic Production Demand Leading CDMOs in the US mRNA therapeutics CDMO market are aggressively expanding their infrastructure and service offerings to capture the explosive growth in the sector. These strategic expansions are critical to supporting the increasingly complex and diverse needs of mRNA therapeutic developers. In a key move in 2024, Catalent broadened its integrated OneBio platform to specifically include development and manufacturing services for mRNA, signaling a strong commitment to the modality. Global giant Lonza is also bolstering its presence through the acquisition of a U.S. manufacturing site from Roche, a move that will significantly increase its biologics capacity. The competitive pressure is also being felt from overseas. In the fourth quarter of 2024, European CDMO BSP revised its strategic plan for 2025-2030, which includes a total planned investment of approximately 600 million Euro. These investments will, in part, support RNA-based onco-vaccines, potentially influencing the global supply chain and increasing competitive options for U.S.-based developers, further energizing the US mRNA therapeutics CDMO market. Pioneering Technological Breakthroughs Redefining mRNA Therapeutic Efficacy and Production Continuous innovation in both therapeutic platforms and manufacturing processes is setting the stage for the next wave of growth. The industry is rapidly moving beyond first-generation mRNA, with development now focused on self-amplifying RNA (saRNA) and circular RNA (circRNA) technologies, which promise longer-lasting immune responses from single, low doses. The potential is immense; preclinical data suggests saRNA vaccines could achieve the desired immune response with a dose that is 100 times lower than current mRNA vaccines. This technological leap could dramatically alter manufacturing requirements and cost structures. To support these advanced products, manufacturing analytics must also evolve. In January 2024, Oxford Nanopore Technologies and Lonza announced a collaboration to validate and market a new, advanced quality control test for mRNA products, addressing a critical need for more precise and efficient production oversight. This focus on next-generation technology will be a key differentiator in the US mRNA therapeutics CDMO market. Need a Customized Version? Request It Now: Diversifying Therapeutic Applications Beyond Infectious Diseases into New Frontiers While infectious diseases provided the initial commercial proof-of-concept, the future of mRNA lies in its application across a much wider spectrum of conditions. As of July 2024, infectious disease applications still accounted for 70% of ongoing mRNA vaccine trials, but the momentum is shifting. Moderna and Merck plan to expand their clinical studies of individualized neoantigen therapy to additional tumor types in 2024. Underscoring this diversification, Moderna's extensive pipeline now includes therapeutics and vaccines for immuno-oncology, rare diseases, and autoimmune diseases. This shift has profound implications for manufacturing. The rise of personalized cancer vaccines, in particular, is driving the need for more tailored, flexible, and smaller-scale GMP-grade RNA production processes in the US mRNA therapeutics CDMO market. The industry is facing the challenge of transitioning from large-scale pandemic production to this new paradigm in 2025, a transition that experts predict will fuel a surge in contract services funding in 2025, for which agile US CDMOs must prepare. U.S. mRNA Therapeutics CDMO Market: ApexBio Technology Biomay AG BioNTech SE Bio-Synthesis, Inc. Catalent, Inc. Danaher (Aldevron) eTheRNA Kaneka Eurogentec S.A. Lonza Recipharm AB Samsung Biologics TriLink BioTechnologies Other Prominent Players Key Market Segmentation: By Application Protein Replacement Therapies Cancer Immunotherapies Viral Vaccines By Indication Cardiovascular & Cerebrovascular Diseases Infectious Diseases Metabolic & Genetic Diseases By End Use Pharmaceutical Companies Government & Academic Research Institutes Biotech Companies Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
